Prelude Therapeutics reports Q3 results

Prelude Therapeutics (PRLD) reported Q3 GAAP EPS loss of $0.12, revenue of $5.6M (down 13% Y/Y), and net loss of $12.5M (down 36% Y/Y). R&D expenses fell 32% to $14.8M, while G&A expenses decreased 2% to $5.1M. The company had $142.7M in cash and equivalents, with a runway into Q2 2028.

Original reporting
Published Nov 16, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Prelude Therapeutics reports Q3 results — source image
Decision brief

The 30-second read

$PRLDBearishMed
01

Why it matters

The earnings miss and revenue decline provide fresh data for traders; the sizable cash position may mitigate immediate risk.

02

Market read

First‑report earnings for a micro‑cap biotech; likely short‑term price impact.

03

What to watch

R&D expense down 32% YoY may indicate cost‑cutting or slower program progress.

Relevance 6/10Novelty 8/10Timing: post‑market release

Background

Prelude Therapeutics issued a press release reporting its Q3 2026 financial results.

Company-level read

Ticker impact

$PRLDBearishMedium confidence
Context

Q3 GAAP EPS loss of $0.12, revenue $5.6M (down 13% YoY), cash $142.7M runway into Q2 2028.

Expected impact

likely downward pressure as investors price the loss and slower revenue growth

Evidence & confidence

The loss per share and revenue decline are new primary data; small‑cap biotech earnings typically move the stock on the day of release.

Market effects

Biotech sector may see modest pullback as a peer reports weaker Q3 results.

U.S. small‑cap biotech investors may adjust exposure.

Limited; impact confined to niche biotech investors.

Counterpoint

Cash runway to 2028 could support a longer‑term upside if pipeline milestones are hit.

Key entities

  • Prelude Therapeutics Incorporated

    Biotech firm reporting Q3 results.

Related articles

$PRLDMed

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated

$PRLDMed

H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy

H.C. Wainwright reiterated a Buy rating and $8.00 price target for Prelude Therapeutics (PRLD), which trades at $3.56. The company announced a clinical trial collaboration with Eli Lilly. Prelude's stock has gained 174% over the past year, with a strong balance sheet. Analysts highlight the potential of its KAT6A-selective degrader, PRT13722, and other drugs in development.

$PRLDMed

Citizens reiterates Prelude Therapeutics stock rating on Lilly deal

Citizens reiterated a Market Outperform rating and $6.00 price target for Prelude Therapeutics (PRLD) after its collaboration with Eli Lilly. PRLD shares are at $3.56, up 174% in a year. The agreement focuses on evaluating PRT13722 in breast cancer trials. Prelude expects clinical updates in 2027 and has a strong cash position of $155.2 million. Other analysts, including JPMorgan and H.C. Wainwright, have also given positive ratings to PRLD.

$PRLDMedAI 8/10

Prelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer Trial

Prelude Therapeutics (PRLD) and Eli Lilly (LLY) will collaborate to evaluate PRT13722 in a breast cancer trial. The Phase 1 study will test PRT13722 with Lilly's Verzenio and Inluriyo in HR+/HER2- breast cancer patients. Prelude's IND application was cleared by the FDA, with enrollment expected in Q4 2026. Preclinical data showed PRT13722's potential as a monotherapy and in combination therapies. PRLD's stock closed at $3.74 on Monday, up 6.42% in pre-market trading.